Biotech combining AAV vectors and synthetic super-enhancers for oncology therapies against aggressive solid tumors.
Founders
Steve Pollard(United Kingdom · ♂)— An Edinburgh cancer-biology and synthetic-biology professor whose research on viral vectors and synthetic enhancers underpins the technology, he co-founded Trogenix in 2024 as CSO to develop precision viral cancer immunotherapies.
Ken Macnamara(United Kingdom · ♂)— A gene-therapy executive with three M&A exits at Synpromics and Bayer/AskBio, he mentored Pollard on startups in Edinburgh and took the CEO role when Trogenix launched in 2024.
In the network
Shares the most investors with (number = shared investors):